Preliminary total net product revenue is expected to total $1.145 billion for full-year 2023
– Preliminary ELEVIDYS net product revenue is expected to be $131.3 million for the fourth quarter and $200.4 million for full-year 2023, significantly exceeding consensus
– Preliminary RNA-based PMO net product revenue for the fourth quarter and full-year of 2023 are expected to total $234.3 million and $945.0 million, respectively, exceeding 2023 full-year guidance of $925 million
– Preliminary year-end 2023 cash, cash equivalents, restricted cash and investments balance of approximately $1.7 billion
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.